Global Cancer Immunotherapy Market - Strategic Insights and Forecasts (2026-2031)

The Global Cancer Immunotherapy Market is forecast to grow at a CAGR of 15.2%, reaching USD 392.0 billion in 2031 from USD 193.4 billion in 2026.

A vital part of oncology, the international market for cancer immunotherapy has been supported by the persistent growth of cancer incidence and ongoing innovation in clinical and regulatory areas; according to the National Cancer Institute, immunotherapy is used to leverage the ability of the body's immune system to identify and destroy cancer cells through the use of several different types of immune therapy drugs. In particular, immune checkpoint inhibitors have been widely used as a method of treatment for many different types of cancers. Increasingly, the need for these types of therapies is supported by government statistics, such as statistics provided by the National Cancer Institute, which estimate that more than 2 million new cancer cases will be diagnosed in the US in 2025, representing a large and growing number of patients who will require effective and innovative treatment options. The National Cancer Institute, also, points to the increasing amount of oncology therapy approvals by the FDA, which granted approval for 46 novel drugs in 2025, with a large majority of these being oncology therapeutic products, suggesting a strong trajectory for the development and commercialisation of immunotherapy. 

Further, ongoing innovation continues to be supported by regulatory mechanisms that create opportunities for quicker approval through mechanisms such as accelerated approval and breakthrough therapy designation. Additionally, the FDA places a high level of importance on the use of biomarker-driven drug development supported by companion diagnostics, providing the opportunity to develop precision-based immunotherapies. 

Overall, the current trends in the global immunotherapy market are characterised by an increase in the number of clinical applications of immunotherapy, a growing number of immune-related therapies in their development pipeline, and strong continued support from the government through approvals of new products and funding for new product research and regulatory initiatives associated with new products.

The chemotherapy landscape is currently going through a fundamental change moving away from its historical position as a stand-alone cytotoxic therapy to its current use as a part of a more comprehensive multi-modal therapy for cancer treatment. Chemotherapy is now more frequently being used in combination with immunotherapy (e.g., checkpoint inhibitors and adoptive cell transfer) therapies as both options to potentially improve cancer outcomes by increasing the likelihood of patients responding to treatment while simultaneously decreasing the likelihood of developing a resistant cancer. The changing landscape of oncology revolves around the concepts of increasing safety, improving efficacy and developing personalised therapeutic regimens whereby the use of chemotherapy will be based on both tumour biology and individual patient factors.

Market Dynamics

Market Drivers

• The global cancer burden is on the rise, with an increase in the number of lung, breast, and colorectal cancer patients driving up demand for chemotherapy. As cancer incidence rates rise due to both the aging population and lifestyle factors; and with chemotherapy being a very accessible and clinically validated treatment that can be used by individuals in any region where there are very few advanced treatments available (e.g., chemotherapy can be delivered to patients in rural areas); therefore, chemotherapy will continue to be an important source of treatment for cancer patients around the world. In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States.

• Chemotherapy in combination with other therapies such as immunotherapy (e.g., monoclonal antibodies, checkpoint inhibitors) has been shown to greatly enhance the efficacy of these combined therapies when compared with chemotherapy alone. The result is a likelihood of greater success for patients being treated for cancer and reinforcing that chemotherapy will remain relevant in today's practice of oncology, resulting in continued usage of chemotherapy across many cancers.

• As the healthcare infrastructure continues to improve in the emerging global economies, the result is continued increasing access to a timely diagnosis and treatment of cancer. Chemotherapy is relatively inexpensive compared to newer therapies and will benefit from this expansion by receiving higher volumes of treatment among the Asia Pacific and other developing economies.

• Advances in technology for drug delivery, including innovations in how chemotherapy drugs are formulated and how they are delivered to patients, result in reducing the adverse effects of chemotherapy and providing improved patient adherence and increasing the potential for chemotherapy to be used as a treatment option for patients who previously were unable to tolerate traditional chemotherapy regimens.

Market Restraints

• High toxicity and severe side effects limit patient adherence and reduce overall treatment acceptance

• Increasing competition from targeted therapies and immunotherapies is gradually reducing chemotherapy’s standalone usage

• Pricing pressures due to generic competition constrain revenue growth despite high treatment volumes

Market Opportunities

• Integrating Immunotherapy: The combining of chemotherapy and immunotherapy methods including both checkpoint inhibitors and cell transfer methods offers an excellent platform for creating an improved immune response and achieving superior survivability; Therefore, chemo will be one of the cornerstones of future cancer treatments.

• Personalized Chemotherapy Regimens: With the use of genomic testing and biomarker determination, personalized chemotherapy regimens can now be developed to minimize toxicity and maximize effectiveness of should therefore raise the value proposition of chemotherapy as part of a precision oncology treatment.

• Emerging New Uses for Chemotherapy: There is a growing body of research supporting the use of chemotherapy in cancers that have previously been treated with little success. For example, combining chemotherapy with newer ways of treating some types of leukemia and bladder cancer has demonstrated significant results.

• New Formulations and Targeted Delivery Mechanisms: The emergence of newer methods of delivering chemotherapy medications will significantly improve the ability to get the medication to its intended target with lower systemic exposure to the chemotherapy medication. As a result of this new research and development, the life cycle and competitiveness of chemotherapy will continue to improve.

Key Developments

• March 2026: Bristol Myers Squibb received FDA approval for Opdivo combined with chemotherapy (AVD) as first-line treatment for advanced classical Hodgkin lymphoma, improving progression-free survival in late-stage patients.

• February 2026: Merck & Co. received FDA approval for Keytruda in combination regimens for platinum-resistant ovarian and related cancers, strengthening immunotherapy adoption in difficult-to-treat gynecologic malignancies.

• November 2025: AstraZeneca announced FDA approval of Imfinzi as the first perioperative immunotherapy for early gastric and gastroesophageal cancers, marking a significant expansion of checkpoint inhibitor use in early-stage oncology.

• September 2025: Merck & Co. secured FDA approval for subcutaneous Keytruda (Keytruda Qlex), enabling faster administration of its PD-1 immunotherapy across multiple solid tumor indications, improving treatment delivery efficiency.

• June 2025: Merck & Co. received U.S. FDA approval for Keytruda as neoadjuvant and adjuvant treatment for resectable locally advanced head and neck cancer, expanding immunotherapy use in earlier-stage disease settings.

Competitive Landscape

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. maintains a strong position through its extensive oncology portfolio and focus on combination therapies integrating chemotherapy with targeted treatments.

Pfizer Inc.

Pfizer Inc. leverages its global presence and diversified oncology pipeline to sustain its chemotherapy market share, particularly in established cancer indications.

Novartis AG

Novartis AG emphasises innovation in drug delivery and combination regimens, strengthening its role in advanced chemotherapy solutions.

Merck & Co., Inc.

Merck & Co., Inc. integrates chemotherapy with its immunotherapy offerings, enhancing treatment efficacy and maintaining competitive positioning.

Bristol-Myers Squibb

Bristol-Myers Squibb Company focuses on synergistic treatment approaches, combining chemotherapy with immuno-oncology therapies to improve patient outcomes.

Market Segmentation

By Type

• Monoclonal antibodies (MABs) dominate due to their targeted action and frequent use in combination with chemotherapy regimens

• Checkpoint Inhibitors are rapidly growing as they enhance immune response when paired with chemotherapy treatments

• Cytokines play a niche role by modulating immune activity but face limitations due to toxicity concerns

• Cancer vaccines are emerging as adjunct therapies that can complement chemotherapy in preventive and therapeutic settings

• Adoptive Cell Transfer shows strong potential in combination strategies but remains limited by high costs and complex procedures

By Application

• Melanoma shows increasing adoption of chemotherapy in combination with immunotherapy to improve response durability

• Lung Cancer represents a major segment where chemotherapy remains a standard of care, especially in advanced stages

• Leukaemias rely on chemotherapy as a core treatment, often combined with targeted therapies for enhanced outcomes

• Bladder Cancer utilises chemotherapy in both neoadjuvant and adjuvant settings to improve surgical outcomes

• Breast Cancer continues to depend heavily on chemotherapy, particularly in aggressive and early-stage cases

• Colorectal Cancer maintains consistent chemotherapy use as part of standard treatment protocols across disease stages

• Others include diverse cancer types where chemotherapy serves as either primary or supportive therapy

By End User

• Hospitals and Clinics dominate due to high patient volumes and access to comprehensive oncology treatment infrastructure

• Cancer Research Centres play a critical role in clinical trials and the development of combination therapies involving chemotherapy

Regional Analysis

North America Market Analysis

North America leads the chemotherapy market due to advanced healthcare infrastructure, high cancer prevalence, and strong adoption of combination therapies. The presence of major pharmaceutical cmpanies and ongoing clinical research further strengthens market growth.

Europe Market Analysis

Europe exhibits steady growth supported by robust healthcare systems and increasing adoption of personalized medicine. Regulatory support for innovative therapies and widespread access to treatment contribute to sustained demand for chemotherapy.

Asia Pacific Market Analysis

Asia Pacific is the fastest-growing region driven by rising cancer incidence, improving healthcare access, and expanding treatment infrastructure. Chemotherapy remains a primary treatment option due to its affordability and availability compared to newer therapies.

Rest of the World

The rest of the world shows gradual growth as healthcare systems develop and access to cancer treatments improves. Chemotherapy remains a key treatment modality due to cost considerations and limited availability of advanced therapies.

Regulatory Landscape

Regulatory frameworks governing the global cancer Immunotherapy market are ongoing, evolving, led primarily by the regulatory agencies responsible for the U.S. Food and Drug Administration (FDA), European Medicines Evaluation Agency (EMEA), and various other National Authorities. The focus of these regulatory agencies is heavily on regulatory authority with regard to safety, efficacy, and precision medicine. As an example of this shift in the regulatory process, the FDA has used mechanisms such as accelerated approval, breakthrough therapy designation, and orphan drug status to expedite the development of immunotherapies to meet the need for therapies in oncology by providing regulatory approval to 46 new drugs, including a variety of therapies directed toward treating cancer, in calendar year 2025. The FY2025 drugs approved represented the continuing evolution of the FDA's regulatory priority of developing advanced biologics and immune-based therapeutic products.

At the same time, the regulatory organizations are performing a significant amount of their regulatory activities with patient-specific treatments approved through the use of companion diagnostics; with biomarkers being utilized more frequently for the submission and approval of an immunotherapy. In such instances, the FDA is providing updated guidance on co-development of drugs with their diagnosis, reinforcing the premise of implementing precision medicine with an immunotherapy approval.

In Europe, the EMEA's regulatory framework will be putting a focus on advanced therapy medicinal products (ATMPs), such as CAR-T cell therapy and gene-modified immunotherapies, through the use of centralised approval and adaptive licensing. The overarching goal of such a regulatory approach in the EU is to facilitate access to drug products, while still providing a high level of pharmacovigilance and post-marketing surveillance.

As with the regulatory organisations in the U.S. and the EU, the global regulatory agencies are implementing regulatory changes by using real-world evidence and adaptive clinical trial approach and lifecycle-based evaluations to assess long-term safety and efficacy of immunotherapies. Due to the increasing complexity associated with immunotherapy (e.g., combination regimens and cell-based therapies), regulatory agencies, industry, and academic institutions are working collaboratively to expedite regulatory approval, while still supporting the clinical rigour necessary for developing successful immunotherapies.

Pipeline Analysis

The international cancer immunotherapy pipeline is developing quickly and is influenced by regulatory activity, including FDA-related regulatory activity and clinical developments reported from government agencies. In 2025, FDA granted a total of 46 drug approvals with a large number pertaining to oncology products, indicating a large late stage immunotherapy and targeted therapy pipeline. A majority of these approvals were based on immuno-oncology modalities including checkpoint inhibitors, bispecific antibodies, and antibody-drug conjugates.

The cancer immunotherapy pipeline also contains advanced cellular therapy products like CAR-T, with new approvals for additional cancer types, including lymphoma. FDA's use of regulatory designations like fast track and breakthrough therapy continues to build momentum for early and mid-stage candidates for colon, lung, and leukaemia cancers.

As we enter 2026 with additional oncology US drug approvals by the FDA that include 1st to market and novel combination therapies, this indicates ongoing pipeline momentum and continued diversification of immunotherapy mechanisms. Thus, the cancer immunotherapy pipeline is moving toward more personalised, combination, and next-generation products.

Strategic Insights and Future Market Outlook

Government-funded research and regulatory acceleration, as well as changing Clinical Guidelines, are increasingly influencing the strategic direction of the Global Cancer Immunotherapy market. Regulatory changes are allowing the FDA to continue expanding their expedited approval pathways for novel immunotherapies such as Checkpoint Inhibitors, Cell-Based Therapies, and Combinations. Recent approvals and label expansions in 2025-2026 show that more Immunotherapies will be used earlier in line and before surgery than just for late-stage cancers. The National Institutes of Health and the associated Cancer Programs focus on Research and Policy to support: Precision Oncology, Early Detection, and Combining Immunotherapy with Other Treatment Options. The data from the government supports approximately 18.6 million Cancer Survivors will be living in the U.S. in 2025, and estimates surpassing 22 million support long-term demand for Immunotherapy.

The Future of the Market is driven by increased use of Biomarker-Driven Therapies, Expanded Use of Combination Therapies and the Use of Real-World Evidence in Regulatory Decision-Making. Government Agencies are also prioritising access to Quality Cancer Care for Everyone and Closing Disparities in Access to Health Care. Continued Public Funding for Clinical Trials and Regulatory Innovations are expected to provide strong growth for Immunotherapy Research and Development, Global Adoption and Manufacturers through the end of 2020's.

Cancer Immunotherapy Market Scope